he purpose of this report was to update the 2006 International League Against Epilepsy (ILAE) report and identify the level of evidence for long-term efficacy or effectiveness for antiepileptic drugs (AEDs) as initial monotherapy for patients with newly diagnosed or untreated epilepsy. All applicable articles from July 2005 until March 2012 were identified, evaluated, and combined with the previous ysis (Glauser et al., 2006) to provide a comprehensive update.
The prior ysis methodology was utilized with three modifications: (1) the detectable noninferiority boundary approach was dropped and both failed superiority studies and prespecified noninferiority studies were yzed using a noninferiority approach, (2) the definition of an adequate comparator was clarified and now includes an absolute minimum point estimate for efficacy/effectiveness, and (3) the relationship table between clinical trial ratings, level of evidence, and conclusions no longer includes a recommendation column to reinforce that this review of efficacy/evidence for specific seizure types does not imply treatment recommendations.
This evidence review contains one clarification: The commission has determined that class I superiority studies can be designed to detect up to a 20% absolute (rather than relative) difference in the point estimate of efficacy/effectiveness between study treatment and comparator using an intent-to-treat ysis. Since July, 2005, three class I randomized controlled trials (RCT) and 11 class III RCTs he been published. The combined ysis (1940-2012) now includes a total of 64 RCTs (7 with class I evidence, 2 with class II evidence) and 11 meta-yses.
New efficacy/effectiveness findings include the following: levetiracetam and zonisamide he level A evidence in s with partial onset seizures and both ethosuximide and valproic acid he level A evidence in children with childhood absence epilepsy.
There are no major changes in the level of evidence for any other subgroup. Levetiracetam and zonisamide join carbamazepine and phenytoin with level A efficacy/effectiveness evidence as initial monotherapy for s with partial onset seizures. Although ethosuximide and valproic acid now he level A efficacy/effectiveness evidence as initial monotherapy for children with absence seizures, there continues to be an alarming lack of well designed, properly conducted epilepsy RCTs for patients with generalized seizures/epilepsies and in children in general.
These findings reinforce the need for multicenter, multinational efforts to design, conduct, and yze future clinically relevant adequately designed RCTs. When selecting a patient's AED, all relevant variables and not just efficacy and effectiveness should be considered.
查看信源地址
上一页:急性附件炎的病因是什么?
下一页:小儿脑瘫的早期有什么临床方法
- 2022-04-28女性癫痫,这些问题你有注目吗?
- 2022-04-202013年世界性抗癫痫联合会抗癫痫药使用指南
- 2022-02-28具体内容的癫痫病病因有哪些
- 2022-01-31未满癫痫病病因有哪些
- 2019-04-21吴忠癫痫病要怎么治疗呢
- 急性附件炎的病因是什么?
- 热播剧《三十》顾佳勇敢地为癫痫儿童发声
- 癫痫发作对中风患者静脉溶栓的长期转移有效
- 诺华银屑病药物 Secukinumab 比依那西普好
- 病例报告:水浴 PUVA 治疗皮下环状肉芽肿
- JAMA:阳性结果的文章一定更受关注吗?
- 银屑病药物 Brodalumab 自杀倾向副作用AZ 遭受重创
- 癫痫猝死:凶手是谁?
- 月经性癫痫患者妊娠期癫痫控制更好
- 他们在对抗子宫腺肌病的路上走了太多弯路!
- 治疗类风湿性关节炎/膝骨关节炎的专家共识
- 划重点!定期体检远离四大妇科威胁!
- 太极拳教程 简单小运动美容抗衰老
- 黑头怎么去?
- 患者饮食不怕热
- 元宵节吃汤圆送灯
- 90%的人误解这些妇科常识!
- 由于医生的原因,物「沉默」而且很难进入处方
- 抗癫痫药物预防新发癫痫:任重而道远
- 原因是什么?
- 油炸刀鱼 酥脆的美味食物
- 临床试验显示XenoPort 银屑病药物胃肠道副作用较严重
- 过年容易得什么病?
- 【用药问答】癫痫发作和局限性发作的首选治疗是什么?
- 病例分享:罕见的双眼孤立性脉络膜黑色素细胞增多
- 夏季生活常识 酷夏保健秘籍你知道多少(2)
- 癫痫形态学:**研究见证分子时代
- 化疗癫痫病药品要怎么化疗好啊
- 羊癫疯治疗原理有哪些 五个治疗原理效果好
- 癫痫病的饮品需要注意什么
- 大脑缺氧 大脑缺氧的征状
- Circ Ep:乙酰试验可鉴别复发AF消融术时的隐匿传导静脉
- 具体内容的癫痫病病因有哪些
- 向对侧转移:部分性癫痫停滞状态
- 癫痫病的以前症状是什么样的
- 初期癫痫病必要采用什么方法来治疗呢
- 樟脑丸所含 樟脑丸有哪些功效
- 小学生课后发呆喊不醒 检查才知得了癫痫病
- 癫痫病频仍的病因有哪些
- 三庚酸酯或可治疗1型转运体缺陷综合症